Literature DB >> 1859154

A two-site immunoradiometric assay for PTH(1-84) using N and C terminal specific monoclonal antibodies.

F C Logue1, B Perry, R S Chapman, I Milne, K James, G H Beastall.   

Abstract

We report the development of a two-site immunoradiometric assay for PTH(1-84) based on two site-specific monoclonal antibodies--3B3 (radiolabelled antibody) specific for PTH(1-34) and ESQ1 (on solid phase) specific for PTH(74-84). Antibody 3B3 is sensitive to the oxidation of the methionine residues in PTH(1-34) therefore hydrogen peroxide (0.1 M) is added to the incubation mixture. Validation studies confirm quantitative recovery of both oxidized and reduced PTH(1-84). The assay has a minimum detection limit of 0.5 pmol/L and a range of 1.5-250 pmol/L with an intra-assay CV of less than 10% (2.8-250 pmol/L less than 5% CV). Studies on clinical samples indicate good discrimination between normal subjects (mean 2.21; range 1.0-5.0 pmol/L) and patients with primary hyperparathyroidism (mean 21.0; range 5.8-100 pmol/L) who in turn are well separated from patients with hypercalcaemia of malignancy (14/18 less than 0.5 pmol/L).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1859154     DOI: 10.1177/000456329102800207

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  7 in total

1.  A comparison of the effects of alfacalcidol treatment and vitamin D2 supplementation on calcium absorption in elderly women with vertebral fractures.

Authors:  R M Francis; I T Boyle; C Moniz; A M Sutcliffe; B S Davis; G H Beastall; R A Cowan; N Downes
Journal:  Osteoporos Int       Date:  1996       Impact factor: 4.507

2.  A comparison of 10 MHz ultrasound and 201-thallium/99m-technetium subtraction scanning in primary hyperparathyroidism.

Authors:  S J Gallacher; P Kelly; J Shand; F C Logue; T Cooke; I T Boyle; J H McKillop
Journal:  Postgrad Med J       Date:  1993-05       Impact factor: 2.401

3.  Factors predicting the acute effect of pamidronate on serum calcium in hypercalcemia of malignancy.

Authors:  S J Gallacher; W D Fraser; F C Logue; F J Dryburgh; R A Cowan; I T Boyle; S H Ralston
Journal:  Calcif Tissue Int       Date:  1992-12       Impact factor: 4.333

4.  Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study.

Authors:  S J Gallacher; J A Fenner; K Anderson; F M Bryden; S W Banham; F C Logue; R A Cowan; I T Boyle
Journal:  Thorax       Date:  1992-11       Impact factor: 9.139

5.  Effects of changes in acid base and calcium concentration on fasting serum insulin, proinsulin, and glucose concentrations.

Authors:  W S Smellie; J O'Donnell; H Davidson; J Couper; F C Logue
Journal:  J Clin Pathol       Date:  1994-11       Impact factor: 3.411

6.  Hypercalcemia of Malignancy Attributed to Cosecretion of PTH and PTHRP in Lung Adenocarcinoma.

Authors:  Jeffrey M Kroopnick; Ubaldo Martinez-Outschoorn; Madalina Tuluc; Caroline S Kim
Journal:  AACE Clin Case Rep       Date:  2021-01-19

7.  Alteration of the circadian rhythm of intact parathyroid hormone and serum phosphate in women with established postmenopausal osteoporosis.

Authors:  W D Fraser; F C Logue; J P Christie; S J Gallacher; D Cameron; D S O'Reilly; G H Beastall; I T Boyle
Journal:  Osteoporos Int       Date:  1998       Impact factor: 5.071

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.